Miguel Ángel Piris Pinilla-rekin lankidetzan egindako argitalpenak (8)

2012

  1. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases

    British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171

2004

  1. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFκB transcription factors

    Journal of Pathology, Vol. 204, Núm. 5, pp. 528-537

  2. Influence of biologic markers on the outcome of Hodgkin's lymphoma: A study by the Spanish Hodgkin's Lymphoma Study Group

    Journal of Clinical Oncology, Vol. 22, Núm. 9, pp. 1664-1673

2000

  1. Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's disease treated with chemotherapy

    Leukemia and Lymphoma, Vol. 39, Núm. 5-6, pp. 563-572

1999

  1. Other cancers in patients with gastric MALT lymphoma

    Leukemia and Lymphoma, Vol. 33, Núm. 1-2, pp. 161-168

1997

  1. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr Virus-latent membrane protein 1 expression

    Blood, Vol. 90, Núm. 6, pp. 2429-2436

1996

  1. Evaluation of the international index in the prognosis of high grade gastric malt lymphoma

    Leukemia and Lymphoma, Vol. 24, Núm. 1-2, pp. 159-163

1995

  1. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients

    Annals of Oncology, Vol. 6, Núm. 4, pp. 355-362